934 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk http://www.zacks.com/stock/news/261771/astrazenecas-bydureon-fails-to-reduce-cardiovascular-risk?cid=CS-ZC-FT-261771 May 24, 2017 - AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers http://www.zacks.com/stock/news/261767/mercks-mrk-keytruda-gets-fda-nod-for-solid-tumor-cancers?cid=CS-ZC-FT-261767 May 24, 2017 - Merck & Co., Inc. (MRK) announced that Keytruda, has received accelerated approval for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors .
Merck & Co's (MRK) Annual Shareholders Meeting Brokers Conference (Transcript) https://seekingalpha.com/article/4075751-merck-and-cos-mrk-annual-shareholders-meeting-brokers-conference-transcript?source=feed_sector_healthcare May 23, 2017 - Merck & Co Inc. (NYSE:MRK) Annual Shareholders Meeting Conference May 23, 2017, 09:00 AM ET Executives Ken Frazier - Chairman and CEO Amy Klug - Executive Director, IR and Assistant Secretary Roge
Merck Presents Phase II Data on Chronic Cough Candidate http://www.zacks.com/stock/news/261647/merck-presents-phase-ii-data-on-chronic-cough-candidate?cid=CS-ZC-FT-261647 May 23, 2017 - Merck (MRK) presented data from a phase II study on its pipeline candidate MK-7264 (formerly AF-219) at the American Thoracic Society (ATS) Annual Conference.
Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion http://www.zacks.com/stock/news/261465/novartis-nvs-lung-cancer-drug-gets-positive-chmp-opinion?cid=CS-ZC-FT-261465 May 22, 2017 - Novartis (NVS) recently announced that the CHMP of the European Medicines Agency (EMA) has recommended the approval of a label expansion of Zykadia.
Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings? http://www.zacks.com/stock/news/261402/merck-vs-sanofi-which-stock-is-a-better-pick-post-q1-earnings?cid=CS-ZC-FT-261402 May 22, 2017 - Merck (MRK) and Sanofi (SNY) are both Zacks Rank #2 (Buy) stocks. Which company looks better-positioned for the remainder of the year?
Amgen Evenity Approval Derailed on Cardiovascular Side Effect http://www.zacks.com/stock/news/261423/amgen-evenity-approval-derailed-on-cardiovascular-side-effect?cid=CS-ZC-FT-261423 May 22, 2017 - A late-stage study at Amgen, Inc. (AMGN) showed that its pipeline candidate Evenity/romosozumab led to a statistically significant superior fracture risk reduction.
Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose http://www.zacks.com/stock/news/261385/mercks-hiv-drug-gets-positive-chmp-opinion-for-higher-dose?cid=CS-ZC-FT-261385 May 22, 2017 - Merck & Co., Inc. (MRK) recently announced that the 600 mg film-coated formulation of its marketed drug, Isentress (raltegravir) in combination with other anti-retroviral therapies, has received positive opinion from CHMP.
3 Top Animal-Health Companies to Buy in 2017 https://www.fool.com/investing/2017/05/21/3-top-animal-health-companies-to-buy-in-2017.aspx?source=iedfolrf0000001 May 21, 2017 - Looking for top animal-health companies to buy? Check out Zoetis, Merck, and Lilly.
Company News for May 19, 2017 http://www.zacks.com/stock/news/261262/company-news-for-may-19-2017?cid=CS-ZC--261262 May 19, 2017 - Companies in the News are: LB,P,INCY,MRK,SHPG

Pages: 1...7879808182838485868788...94

<<<Page 83>